Effects of aspirin on the gastrointestinal tract: Pros vs. cons (Review)
- Authors:
- Zhuoya Li
- Zheng Wang
- Baile Shen
- Chen Chen
- Xiaoyun Ding
- Haojun Song
-
Affiliations: Department of Internal Medicine, The Medical School of Ningbo University, Ningbo, Zhejiang 315000, P.R. China, Department of Gastroenterology, Ningbo First Hospital, Ningbo, Zhejiang 315000, P.R. China - Published online on: July 6, 2020 https://doi.org/10.3892/ol.2020.11817
- Pages: 2567-2578
-
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Jemal A, Center MM, DeSantis C and Ward EM: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Onyoh EF, Hsu WF, Chang LC, Lee YC, Wu MS and Chiu HM: The rise of colorectal cancer in asia: Epidemiology, screening, and management. Curr Gastroenterol Rep. 21:362019. View Article : Google Scholar : PubMed/NCBI | |
|
Rahman R, Asombang AW and Ibdah JA: Characteristics of gastric cancer in Asia. World J Gastroenterol. 20:4483–4490. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wick JY: Aspirin: A history, A love story. Consult Pharm. 27:322–329. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, Jaffe AS, Jneid H, Kelly RF, Kontos MC, et al: 2014 AHA/ACC Guideline for the management of patients with Non-ST-Elevation acute coronary syndromes: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Colle Cardiol. 64:2645–2687. 2014. View Article : Google Scholar | |
|
Antithrombotic Trialists' (ATT) Collaboration, . Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, et al: Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet. 373:1849–1860. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Roffi M, Patrono C, Collet J, Mueller C, Valgimigli M, Andreotti F, Bax J, Borger M, Brotons C, Chew DP, et al: 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-Segment Elevation of the European Society of Cardiology (ESC). G Ital Cardiol (Rome). 17:831–872. 2016.(In Italian). PubMed/NCBI | |
|
Smith DK, Demetriou T and Weber C: Aspirin for primary prevention: USPSTF recommendations for CVD and colorectal cancer. J Fam Pract. 68:146–151. 2019.PubMed/NCBI | |
|
Ventura L, Miccinesi G, Barchielli A, Manneschi G, Puliti D, Mantellini P, Orso F and Zappa M: Does low-dose aspirin use for cardiovascular disease prevention reduce colorectal cancer deaths? A comparison of two cohorts in the Florence district, Italy. Eur J Cancer Prev. 27:134–139. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Bibbins-Domingo K; U.S. Preventive Services Task Force, : Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 164:836–845. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Cea Soriano L, Soriano-Gabarró M and García Rodríguez LA: Incidence of colorectal cancer in new users and non-users of low-dose aspirin without existing cardiovascular disease: A cohort study using The Health Improvement Network. Int J Cardiol. 248:376–381. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Soon S, Chia WJ, Redekop K and Wee HL: A Cost-effectiveness analysis of aspirin in the primary prevention of cardiovascular diseases and colorectal cancer. Value Health. 18:A4622015. View Article : Google Scholar | |
|
Lanas A and Gargallo CJ: Management of low-dose aspirin and clopidogrel in clinical practice: A gastrointestinal perspective. J Gastroenterol. 50:626–637. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lanas A and Scheiman J: Low-dose aspirin and upper gastrointestinal damage: Epidemiology, prevention and treatment. Curr Med Res Opin. 23:163–173. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Yuhara H, Corley DA, Nakahara F, Nakajima T, Koike J, Igarashi M, Suauki T and Mine T: Aspirin and non-aspirin NSAIDs increase risk of colonic diverticular bleeding: A systematic review and meta-analysis. J Gastroenterol. 49:992–1000. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Strum WB: Colorectal adenomas. N Engl J Med. 374:1065–1075. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Giovannucci E, Rimm E, Stampfer M, Colditz G, Ascherio A and Willett WC: Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 121:241–246. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Thun MJ, Namboodiri MM and Heath C Jr: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 325:1593–1596. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Sandler R, Halabi S, Baron J, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas J, Karp D, Loprinzi CL, et al: A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 348:883–890. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, et al: A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 348:891–899. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Half E, Bercovich D and Rozen P: Familial adenomatous polyposis. Orphanet J Rare Dis. 4:222009. View Article : Google Scholar : PubMed/NCBI | |
|
Aihara H, Kumar N and Thompson CC: Diagnosis, surveillance, and treatment strategies for familial adenomatous polyposis: Rationale and update. Eur J Gastroenterol Hepatol. 26:255–262. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Iwama T, Tamura K, Morita T, Hirai T, Hasegawa H, Koizumi K, Shirouzu K, Sugihara K, Yamamura T, Muto T, et al: A clinical overview of familial adenomatous polyposis derived from the database of the polyposis registry of Japan. Int J Clin Oncol. 9:308–316. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Jasperson K and Burt RW: The genetics of colorectal cancer. Surg Oncol Clin N Am. 24:683–703. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ishikawa H: Chemoprevention of carcinogenesis in familial tumors. Int J Clin Oncol. 9:299–303. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Ishikawa H, Wakabayashi K, Suzuki S, Mutoh M, Hirata K, Nakamura T, Takeyama I, Kawano A, Gondo N, Abe T, et al: Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: Double-blind, randomized clinical trial. Cancer Med. 2:50–56. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Burn J, Bishop DT, Chapman PD, Elliott F, Bertario L, Dunlop MG, Eccles D, Ellis A, Evans DG, Fodde R, et al: A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila). 4:655–665. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Cea Soriano L, Soriano-Gabarró M and Garcia Rodríiguez LA: Incidence of colorectal cancer in new users and non-users of low-dose aspirin without existing cardiovascular disease: A cohort study using The Health Improvement Network. Int J Cardiol. 248:376–381. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Cao Y, Nishihara R, Wu K, Wang M, Ogino S, Willett WC, Spiegelman D, Fuchs CS, Giovannucci EL and Chan AT: Population-wide impact of long-term use of aspirin and the risk for cancer. JAMA Oncol. 2:762–769. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Thun MJ, Henley SJ and Patrono C: Nonsteroidal Anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. J Nat Cancer Inst. 94:252–266. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, Lee R, Belch JF, Wilson M, Mehta Z and Meade TW: Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: Analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 379:1602–1612. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Chubak J, Whitlock EP, Williams SB, Kamineni A, Burda BU, Buist DS and Anderson ML: Aspirin for the prevention of cancer incidence and mortality: Systematic evidence reviews for the U.S. Preventive Services Task Force. Ann Intern Med. 164:814–825. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Flossmann E and Rothwell PM; British Doctors Aspirin Trial and the UK-TIA Aspirin Trial, : Effect of aspirin on long-term risk of colorectal cancer: Consistent evidence from randomised and observational studies. Lancet. 369:1603–1613. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP and Meade TW: Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 376:1741–1750. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Li XF, Xu BZ and Wang SZ: Aspirin inhibits the proliferation and migration of gastric cancer cells in p53-knockout mice. Oncol Lett. 12:3183–3186. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR and Hawk E: Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res. 24:3177–3184. 2004.PubMed/NCBI | |
|
Thun MJ, Namboodiri MM, Calle EE, Flanders WD and Heath CW Jr: Aspirin use and risk of fatal cancer. Cancer Res. 53:1322–1327. 1993.PubMed/NCBI | |
|
Rothwell PM, Fowkes FGR, Belch JFF, Ogawa H, Warlow CP and Meade TW: Effect of daily aspirin on long-term risk of death due to cancer: Analysis of individual patient data from randomised trials. Lancet. 377:31–41. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Farrow DC, Vaughan TL, Hansten PD, Stanford JL, Risch HA, Gammon MD, Chow WH, Dubrow R, Ahsan H, Mayne ST, et al: Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev. 7:97–102. 1998.PubMed/NCBI | |
|
Vaughan TL, Dong LM, Blount PL, Ayub K, Odze RD, Sanchez CA, Rabinovitch PS and Reid BJ: Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: A prospective study. Lancet Oncol. 6:945–952. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
González-Pérez A, Rodríguez LAG and LópezRidaura R: Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: A meta-analysis. BMC Cancer. 3:282003. View Article : Google Scholar : PubMed/NCBI | |
|
Liu JF, Jamieson GG, Wu TC, Zhu GJ and Drew PA: A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia. Ann Surg Oncol. 16:1397–1402. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Frouws MA, Bastiaannet E, Langley RE, Chia WK, van Herk-Sukel MP, Lemmens VE, Putter H, Hartgrink HH, Bonsing BA, Van de Velde CJ, et al: Effect of low-dose aspirin use on survival of patients with gastrointestinal malignancies; an observational study. Br J Cancer. 116:405–413. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Macfarlane TV, Murchie P and Watson MC: Aspirin and other non-steroidal anti-inflammatory drug prescriptions and survival after the diagnosis of head and neck and oesophageal cancer. Cancer Epidemiol. 39:1015–1022. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Bosetti C, Rosato V, Gallus S, Cuzick J and La Vecchia C: Aspirin and cancer risk: A quantitative review to 2011. Ann Oncol. 23:1403–1415. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Jankowski JAZ, de Caestecker J, Love SB, Reilly G, Watson P, Sanders S, Ang Y, Morris D, Bhandari P, Brooks C, et al: Esomeprazole and aspirin in Barrett's oesophagus (AspECT): A randomised factorial trial. Lancet. 392:400–408. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Spence AD, Busby J, Johnston BT, Baron JA, Hughes CM, Coleman HG and Cardwell CR: Low-Dose aspirin use does not increase survival in 2 independent population-based cohorts of patients with esophageal or gastric cancer. Gastroenterology. 154:849–860.e1. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Choi JH, Lee SH, Huh G, Chun JW, You MS, Paik WH, Ryu JK and Kim YT: The association between use of statin or aspirin and pancreatic ductal adenocarcinoma: A nested case-control study in a Korean nationwide cohort. Cancer Med. 8:7419–7430. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sahasrabuddhe VV, Gunja MZ, Graubard BI, Trabert B, Schwartz LM, Park Y, Hollenbeck AR, Freedman ND and McGlynn KA: Nonsteroidal Anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J Natl Cancer Inst. 104:1808–1814. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD and Shapiro S: Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev. 9:119–123. 2000.PubMed/NCBI | |
|
Petrick JL, Sahasrabuddhe VV, Chan AT, Alavanja MC, Beane-Freeman LE, Buring JE, Chen J, Chong DQ, Freedman ND, Fuchs CS, et al: NSAID use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The liver cancer pooling project. Cancer Prev Res. 8:1156–1162. 2015. View Article : Google Scholar | |
|
Singh S, Singh PP, Roberts LR and Sanchez W: Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 11:45–54. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Hawk ET, Umar A and Viner JL: Colorectal cancer chemoprevention-an overview of the science 1 1 This article was prepared in our capacity as employees of the U.S. Federal Government. Gastroenterology. 126:1423–1447. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Elwood PC, Gallagher AM, Duthie GG, Mur LA and Morgan G: Aspirin, salicylates, and cancer. Lancet. 373:1301–1309. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Pasche B, Wang M, Pennison M and Jimenez H: Prevention and treatment of cancer with aspirin: Where do we stand? Semin Oncol. 41:397–401. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Mahboubi Rabbani SMI and Zarghi A: Selective COX-2 inhibitors as anticancer agents: A patent review (2014–2018). Expert Opin Ther Pat. 29:407–427. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Poorani R, Bhatt AN, Dwarakanath BS and Das UN: COX-2, aspirin and metabolism of arachidonic, eicosapentaenoic and docosahexaenoic acids and their physiological and clinical significance. Eur J Pharmacol. 785:116–132. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang D and Dubois RN: Prostaglandins and cancer. Gut. 55:115–122. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Chell S, Kaidi A, Williams AC and Paraskeva C: Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer. Biochim Biophys Acta. 1766:104–119. 2006.PubMed/NCBI | |
|
Chan AT, Ogino S and Fuchs CS: Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 356:2131–2142. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, Yu J, Park BH, Kinzler KW and Vogelstein B: Role of BAX in the apoptotic response to anticancer agents. Science. 290:989–992. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Z and Dubois RN: Par-4, a proapoptotic gene, is regulated by NSAIDs in human colon carcinoma cells. Gastroenterol. 118:1012–1017. 2000. View Article : Google Scholar | |
|
Kashfi K and Rigas B: Non-COX-2 targets and cancer: Expanding the molecular target repertoire of chemoprevention. Biochem Pharmacol. 70:969–986. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Shureiqi I, Xu X, Chen D, Lotan R, Morris JS, Fischer SM and Lippman SM: Nonsteroidal anti-inflammatory drugs induce apoptosis in esophageal cancer cells by restoring 15-lipoxygenase-1 expression. Cancer Res. 61:4879–4884. 2001.PubMed/NCBI | |
|
Elmore S: Apoptosis: A review of programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
McIlhatton MA, Tyler J, Burkholder S, Ruschoff J, Rigas B, Kopelovich L and Fishel R: Nitric Oxide-donating aspirin derivatives suppress microsatellite instability in mismatch repair-deficient and hereditary nonpolyposis colorectal cancer cells. Cancer Res. 67:10966–10975. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Rüschoff J, Wallinger S, Dietmaier W, Bocker T, Brockhoff G, Hofstädter F and Fishel R: Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. Proc Natl Acad Sci USA. 95:11301–11306. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Goel A, Chang DK, Ricciardiello L, Gasche C and Boland CR: A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. Clin Cancer Res. 9:383–390. 2003.PubMed/NCBI | |
|
Huang Z, Fang W, Liu W, Wang L, Liu B and Liu S and Liu S: Aspirin induces Beclin-1-dependent autophagy of human hepatocellular carcinoma cell. Eur J Pharmacol. 823:58–64. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Bhattacharya A and Eissa NT: Autophagy and autoimmunity crosstalks. Front Immunol. 4:882013. View Article : Google Scholar : PubMed/NCBI | |
|
Henry WS, Laszewski T, Tsang T, Beca F, Beck AH, McAllister SS and Toker A: Aspirin suppresses growth in PI3K-mutant breast cancer by activating AMPK and inhibiting mTORC1 signaling. Cancer Res. 77:790–801. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Liu W, Jiang Y, Sun J, Geng S, Pan Z, Prinz RA, Wang C, Sun J, Jiao X and Xu X: Activation of TGF-β-activated kinase 1 (TAK1) restricts Salmonella Typhimurium growth by inducing AMPK activation and autophagy. Cell Death Dis. 9:5702018. View Article : Google Scholar : PubMed/NCBI | |
|
Hardie DG, Ross FA and Hawley SA: AMP-Activated protein kinase: A target for drugs both ancient and modern. Chem Biol. 19:1222–1236. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kostadinov RL, Kuhner MK, Li X, Sanchez CA, Galipeau PC, Paulson TG, Sather CL, Srivastava A, Odze RD, Blount PL, et al: NSAIDs modulate clonal evolution in Barrett's esophagus. PLoS Genet. 9:e10035532013. View Article : Google Scholar : PubMed/NCBI | |
|
Drew DA, Cao Y and Chan AT: Aspirin and colorectal cancer: The promise of precision chemoprevention. Nat Rev Cancer. 16:173–186. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Gala MK and Chan AT: Molecular pathways: Aspirin and Wnt signaling-a molecularly targeted approach to cancer prevention and treatment. Clin Cancer Res. 21:1543–1548. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yeomans ND, Lanas AI, Talley NJ, Thomson AB, Daneshjoo R, Eriksson B, Appelman-Eszczuk S, Långström G, Naesdal J, Serrano P, et al: Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther. 22:795–801. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Cayla G, Collet JP, Silvain J, Thiefin G, Woimant F and Montalescot G: Prevalence and clinical impact of Upper Gastrointestinal Symptoms in subjects treated with low dose aspirin: The UGLA survey. Int J Cardiol. 156:69–75. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Biondi-Zoccai GG, Lotrionte M, Agostoni P, Abbate A, Fusaro M, Burzotta F, Testa L, Sheiban I and Sangiorgi G: A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J. 27:2667–2674. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Baron JA, Senn S, Voelker M, Lanas A, Laurora I, Thielemann W, Bruckner A and McCarthy D: Gastrointestinal adverse effects of short-term aspirin use: A meta-analysis of published randomized controlled trials. Drugs R D. 13:9–16. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Cayla G, Collet JP, Silvain J, Thiefin G, Woimant F and Montalescot G: Prevalence and clinical impact of Upper Gastrointestinal Symptoms in subjects treated with low dose aspirin: The UGLA survey. Int J Cardiol. 156:69–75. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yeomans ND and Naesdal J: Systematic review: Ulcer definition in NSAID ulcer prevention trials. Aliment Pharmacol Ther. 27:465–472. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Cryer B and Feldman M: Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology. 117:17–25. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Papatheodoridis GV, Sougioultzis S and Archimandritis AJ: Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: Systematic review. Clin Gastroenterol Hepatol. 4:130–142. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Huang JQ, Sridhar S and Hunt RH: Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: A meta-analysis. Lancet. 359:14–22. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Thorat MA and Cuzick J: Prophylactic use of aspirin: Systematic review of harms and approaches to mitigation in the general population. Eur J Epidemiol. 30:5–18. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Iwamoto J, Mizokami Y, Shimokobe K, Ito M, Hirayama T, Saito Y, Ikegami T, Honda A and Matsuzaki Y: Clinical features of gastroduodenal ulcer in Japanese patients taking low-dose aspirin. Dig Dis Sci. 55:2270–2274. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Garcia Rodriguez LA, Martin-Perez M, Hennekens CH, Rothwell PM and Lanas A: Bleeding Risk with long-term low-dose aspirin: A systematic review of observational studies. PLoS One. 11:e01600462016. View Article : Google Scholar : PubMed/NCBI | |
|
McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, Reid CM, Lockery JE, Kirpach B, Storey E, et al: Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 379:1509–1518. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
de Abajo FJ and García Rodríguez LA: Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol. 1:12001. View Article : Google Scholar : PubMed/NCBI | |
|
Lanas A, Serrano P, Bajador E, Esteva F, Benito R and Sáinz R: Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology. 112:683–689. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Yamada A, Sugimoto T, Kondo S, Ohta M, Watabe H, Maeda S, Togo G, Yamaji Y, Ogura K, Okamoto M, et al: Assessment of the risk factors for colonic diverticular hemorrhage. Dis Colon Rectum. 51:116–120. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Lanas Á, Carrera-Lasfuentes P, Arguedas Y, García S, Bujanda L, Calvet X, Ponce J, Perez-Aísa Á, Castro M, Muñoz M, et al: Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol. 13:906–912.e2. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hirata Y, Kataoka H, Shimura T, Mizushima T, Mizoshita T, Tanida S, Kamiya T and Joh T: Incidence of gastrointestinal bleeding in patients with cardiovascular disease: Buffered aspirin versus enteric-coated aspirin. Scand J Gastroenterol. 46:803–809. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Nagata N, Niikura R, Aoki T, Shimbo T, Kishida Y, Sekine K, Tanaka S, Watanabe K, Sakurai T, Yokoi C, et al: Colonic diverticular hemorrhage associated with the use of nonsteroidal anti-inflammatory drugs, low-dose aspirin, antiplatelet drugs, and dual therapy. J Gastroenterol Hepatol. 29:1786–1793. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Reichert MC, Krawczyk M, Appenrodt B, Casper M, Friesenhahn-Ochs B, Grünhage F, Jüngst C, Zimmer V, Lammert F and Dauer M: Selective association of nonaspirin NSAIDs with risk of diverticulitis. Int J Colorectal Dis. 33:423–430. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Strate LL, Liu YL, Huang ES, Giovannucci EL and Chan AT: Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding. Gastroenterology. 140:1427–1433. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
O'Connor N, Dargan PI and Jones AL: Hepatocellular damage from non-steroidal anti-inflammatory drugs. QJM. 96:787–791. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
McNeil JJ, Nelson MR, Woods RL, Lockery JE, Wolfe R, Reid CM, Kirpach B, Shah RC, Ives DG, Storey E, et al: Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med. 379:1519–1528. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L, et al: Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: An analysis from the CAPP2 randomised controlled trial. Lancet. 378:2081–2087. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Würtz M and Grove EL: Interindividual variability in the efficacy of oral antiplatelet drugs: Definitions, mechanisms and clinical importance. Curr Pharm Des. 18:5344–5361. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Rocca B and Petrucci G: Variability in the responsiveness to low-dose aspirin: Pharmacological and disease-related mechanisms. Thrombosis. 2012:3767212012. View Article : Google Scholar : PubMed/NCBI | |
|
Joharatnam-Hogan N, Cafferty F, Hubner R, Swinson D, Sothi S, Gupta K, Falk S, Patel K, Warner N, Kunene V, et al: Aspirin as an adjuvant treatment for cancer: Feasibility results from the Add-Aspirin randomised trial. Lancet Gastroenterol Hepatol. 4:854–862. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kaufman DW, Kelly JP, Wiholm BE, Laszlo A, Sheehan JE, Koff RS and Shapiro S: The risk of acute major upper gastrointestinal bleeding among users of aspirin and ibuprofen at various levels of alcohol consumption. Am J Gastroenterol. 94:3189–3196. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Hernández-Díaz S and García Rodríguez LA: Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med. 4:22–20. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW and Quigley EM; American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents, : ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 118:1894–1909. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS and Shapiro S: Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet. 348:1413–1416. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Lin KJ, Hernández-Díaz S and García Rodríguez LA: Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. Gastroenterology. 141:71–79. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Sylvester KW, Cheng JW and Mehra MR: Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events. Vasc Health Risk Manag. 9:245–254. 2013.PubMed/NCBI | |
|
Lanas A, Polo-Tomas M and Casado-Arroyo R: The aspirin cardiovascular/gastrointestinal risk calculator-a tool to aid clinicians in practice. Aliment Pharmacol Ther. 37:738–748. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Mo C, Sun G, Lu ML, Zhang L, Wang YZ, Sun X and Yang YS: Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries. World J Gastroenterol. 21:5382–5392. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Scally B, Emberson JR, Spata E, Reith C, Davies K, Halls H, Holland L, Wilson K, Bhala N, Hawkey C, et al: Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: A meta-analysis of randomised trials. Lancet Gastroenterol Hepatol. 3:231–241. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Whellan DJ, Goldstein JL, Cryer BL, Eisen GM, Lanas A, Miller AB, Scheiman JM, Fort JG, Zhang Y and O'Connor C: PA32540 (a coordinated-delivery tablet of enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) versus enteric-coated aspirin 325 mg alone in subjects at risk for aspirin-associated gastric ulcers: Results of two 6-month, phase 3 studies. Am Heart J. 168:495–502.e4. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Martín Merino E, Johansson S, Nagy P and García Rodríguez LA: Effect of baseline gastrointestinal risk and use of proton pump inhibitors on frequency of discontinuation of aspirin for secondary cardiovascular prevention in united kingdom primary care. Am J Cardiol. 112:1075–1082. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Dey AB: World report on ageing and health. Indian J Med Res. 145:1502017. View Article : Google Scholar | |
|
Hull MA, Sprange K, Hepburn T, Tan W, Shafayat A, Rees CJ, Clifford G, Logan RF, Loadman PM, Williams EA, et al: Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): A multicentre, randomised, double-blind, placebo-controlled, 2×2 factorial trial. Lancet. 392:2583–2594. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, Chaussade S and Baron JA: Aspirin for the chemoprevention of colorectal adenomas: Meta-analysis of the randomized trials. J Natl Cancer Inst. 101:256–266. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Cook NR, Lee IM, Zhang SM, Moorthy MV and Buring JE: Alternate-day, low-dose aspirin and cancer risk: Long-term observational follow-up of a randomized trial. Ann Intern Med. 159:77–85. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kuan YC, Huang KW, Lin CL, Luo JC and Kao CH: Effects of aspirin or clopidogrel on colorectal cancer chemoprevention in patients with type 2 diabetes mellitus. Cancers (Basel). 11:14682019. View Article : Google Scholar | |
|
Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW and Mehta Z: Effect of daily aspirin on risk of cancer metastasis: A study of incident cancers during randomised controlled trials. Lancet. 379:1591–1601. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Chan FK, Leung Ki EL, Wong GL, Ching JY, Tse YK, Au KW, Wu JC and Ng SC: Risks of bleeding recurrence and cardiovascular events with continued aspirin use after lower gastrointestinal hemorrhage. Gastroenterology. 151:271–277. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Casado Arroyo R, Polo-Tomas M, Roncales MP, Scheiman J and Lanas A: Lower GI bleeding is more common than upper among patients on dual antiplatelet therapy: Long-term follow-up of a cohort of patients commonly using PPI co-therapy. Heart. 98:718–723. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Smecuol E, Pinto Sanchez MI, Suarez A, Argonz JE, Sugai E, Vazquez H, Litwin N, Piazuelo E, Meddings JB, Bai JC and Lanas A: Low-dose aspirin affects the small bowel mucosa: Results of a pilot study with a multidimensional assessment. Clin Gastroenterol Hepatol. 7:524–529. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Moore RA, Derry S and McQuay HJ: Faecal blood loss with aspirin, nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors: Systematic review of randomized trials using autologous chromium-labelled erythrocytes. Arthritis Res Ther. 10:R72008. View Article : Google Scholar : PubMed/NCBI | |
|
Endo H, Higurashi T, Hosono K, Sakai E, Sekino Y, Iida H, Sakamoto Y, Koide T, Takahashi H, Yoneda M, et al: Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: A pilot randomized controlled study. J Gastroenterol. 46:894–905. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Montalto M, Gallo A, Curigliano V, D'Onofrio F, Santoro L, Covino M, Dalvai S, Gasbarrini A and Gasbarrini G: Clinical trial: The effects of a probiotic mixture on non-steroidal anti-inflammatory drug enteropathy-a randomized, double-blind, cross-over, placebo-controlled study. Aliment Pharmacol Ther. 32:209–214. 2010. View Article : Google Scholar : PubMed/NCBI |
